The Combination of rTMS and Pharmacotherapy on In Vitro Models: A Mini-Review

Author(s): Chryssa Pourzitaki*, Ioannis Dardalas, Frideriki Poutoglidou, Dimitrios Kouvelas, Vasilios K. Kimiskidis

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 19 , Issue 3 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique that is being actively explored as a potential therapeutic modality in various neuropsychiatric disorders, such as depression, neuropathic pain, epilepsy, multiple sclerosis, and neurodegenerative disorders, including the Parkinson’s and Alzheimer’s disease. The Food and Drug Administration (FDA) approved rTMS for the treatment of major depression, migraine-associated headaches, and Obsessive Compulsive Disorder (OCD). The fact that a significant proportion of patients suffering from these disorders fail to respond to current pharmacological interventions indicates the need for alternative therapies like rTMS.

Objective: The objective was to find and summarize all studies combining the use of rTMS and pharmacological interference in vitro, in order to facilitate future studies.

Methods: The results of studies combining the use of rTMS with pharmacological interference in vitro were focused on. The PubMed database was searched using the terms “rTMS”, “repetitive”, “transcranial”, “magnetic”, “stimulation”, “in vitro”, “in vivo”, “cell cultures” untilMarch 2019 and 7 eligible studies were found.

Results: Overall results show a synergistic effect of rTMS and pharmacotherapy in vitro with additive effectiveness, better prognosis, and superior potential management.

Conclusion: The limited amount of knowledge denotes the need for additional in vitro studies on the combination of rTMS and pharmacotherapy, which could be extended to in vivo studies and ultimately help design clinical trials so as to improve the therapeutic management of patients with a wide array of neuropsychiatric disorders.

Keywords: rTMS, repetitive magnetic stimulation, pharmacotherapy, in vitro, neuropsychiatric disorders, Obsessive Compulsive Disorder (OCD).

[1]
Habib S, Hamid U, Jamil A, et al. Transcranial magnetic stimulation as a therapeutic option for neurologic and psychiatric illnesses. Cureus 2018; 10(10): e3456.
[http://dx.doi.org/10.7759/cureus.3456] [PMID: 30564535]
[2]
Hama A, Natsume T, Ogawa SY, et al. Pain-related behavior and brain activation in a cynomolgus macaque model of postoperative pain. CNS Neurol Disord Drug Targets 2018; 17(5): 348-60.
[http://dx.doi.org/10.2174/1871527317666180515121350]
[3]
Schweiger V, Martini A, Bellamoli P, et al. Ultramicronized palmitoylethanolamide (um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): retrospective observational study on 407 patients. CNS Neurol Disord Drug Targets 2019; 18(4): 326-33.
[4]
Zhang XQ, Li L, Huo JT, Cheng M, Li LH. Effects of repetitive transcranial magnetic stimulation on cognitive function and cholinergic activity in the rat hippocampus after vascular dementia. Neural Regen Res 2018; 13(8): 1384-9.
[http://dx.doi.org/10.4103/1673-5374.235251] [PMID: 30106050]
[5]
Nasios G, Messinis L, Dardiotis E, Papathanasopoulos P. Repetitive transcranial magnetic stimulation, cognition, and multiple sclerosis: an overview. Behav Neurol 2018; 2018: 8584653.
[http://dx.doi.org/10.1155/2018/8584653]
[6]
Balea M, Muresanu D, Alvarez A, et al. VaD-An integrated framework for cognitive rehabilitation. CNS Neurol Disord Drug Targets 2018; 17(1): 22-33.
[http://dx.doi.org/10.2174/1871527317666180219164545]
[7]
Di Nuzzo C, Ruggiero F, Cortese F, Cova I, Priori A, Ferrucci R. Non-invasive cerebellar stimulation in cerebellar disorders. CNS Neurol Disord Drug Targets 2018; 17(3): 193-8.
[http://dx.doi.org/10.2174/1871527317666180404113444]
[8]
Lefaucheur JP, André-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014; 125(11): 2150-206.
[http://dx.doi.org/10.1016/j.clinph.2014.05.021] [PMID: 25034472]
[9]
Onesti E, Frasca V, Ceccanti M, et al. Short-term ultramicronized palmitoylethanolamide therapy in patients with myasthenia gravis: a pilot study to possible future implications of treatment. CNS Neurol Disord Drug Targets 2019; 18(3): 232-8.
[http://dx.doi.org/10.2174/1871527318666190131121827]
[10]
Cirillo G, Di Pino G, Capone F, et al. Neurobiological after-effects of non-invasive brain stimulation. Brain Stimul 2017; 10(1): 1-18.
[http://dx.doi.org/10.1016/j.brs.2016.11.009] [PMID: 27931886]
[11]
Kumar A, Datusalia AK. Metabolic Stress and inflammation: implication in treatment for neurological disorders. CNS Neurol Disord Drug Targets 2018; Nov 117(9): 642-3.
[12]
Szpisjak L, Zadori D, Klivenyi P, Vecsei L. Clinical characteristics and possible drug targets in autosomal dominant spinocerebellar ataxias. CNS Neurol Disord Drug Targets 2019; 18(4): 279-93.
[13]
Chervyakov AV, Chernyavsky AY, Sinitsyn DO, Piradov MA. Possible mechanisms underlying the therapeutic effects of transcranial magnetic stimulation. Front Hum Neurosci 2015; 9: 303.
[http://dx.doi.org/10.3389/fnhum.2015.00303] [PMID: 26136672]
[14]
Martin-Trias P, Bragulat V, Peña-Gómez C, et al. Translational challenge models in support of efficacy studies: neurobehavioral and cognitive changes induced by transcranial magnetic stimulation in healthy volunteers. CNS Neurol Disord Drug Targets 2016; 115(7): 802-15.
[http://dx.doi.org/10.2174/1871527315666160518124316]
[15]
Medina-Fernandez FJ, Escribano BM, Tunez I. COMMENTARY: transcranial magnetic stimulation in multiple sclerosis: a method to improve movement. CNS Neurol Disord Drug Targets 2017; 16(3): 218-9.
[http://dx.doi.org/10.2174/1871527316666170116161134] [PMID: 28901849]
[16]
Estrada C, Tarragon EB, Kelley J, et al. Transcranial magnetic stimulation on rodent models. CNS Neurol Disord Drug Targets 2016; 115(7): 756-64.
[http://dx.doi.org/10.2174/1871527315666160518125341]
[17]
Escribano B, Santamaría A, E, de Lima M, J, Medina-Fernández F, Bashir S, Túnez I. Brain magnetic stimulation in animal models: a valuable lesson for clinical applications. CNS Neurol Disord Drug Targets 2016; 115(7): 845-56.
[http://dx.doi.org/10.2174/1871527315666160527152547]
[18]
Soundara Rajan T, Ghilardi MFM, Wang HY, et al. Mechanism of action for rTMS: a working hypothesis based on animal studies. Front Physiol 2017; 8: 457.
[http://dx.doi.org/10.3389/fphys.2017.00457] [PMID: 28713286]
[19]
Durmaz O, Ateş MA, Şenol MG. ŞENOL MG. Repetitive transcranial magnetic stimulation (rTMS)-induced trigeminal autonomic cephalalgia. Noro Psikiyatri Arsivi 2015; 52(3): 309-11.
[http://dx.doi.org/10.5152/npa.2015.7618] [PMID: 28360729]
[20]
Grehl S, Martina D, Goyenvalle C, Deng ZD, Rodger J, Sherrard RM. In vitro magnetic stimulation: a simple stimulation device to deliver defined low intensity electromagnetic fields. Front Neural Circuits 2016; 10: 85.
[http://dx.doi.org/10.3389/fncir.2016.00085] [PMID: 27857683]
[21]
Zheng Y, Ma XX, Dong L, Ma W, Cheng JH. Effects of uninterrupted sinusoidal LF-EMF stimulation on LTP induced by different combinations of TBS/HFS at the Schaffer collateral-CA1 of synapses. Brain Res 2019; 1725: 146487.
[http://dx.doi.org/10.1016/j.brainres.2019.146487] [PMID: 31580873]
[22]
Chen YH, Zhang RG, Xue F, et al. Quetiapine and repetitive transcranial magnetic stimulation ameliorate depression-like behaviors and up-regulate the proliferation of hippocampal-derived neural stem cells in a rat model of depression: the involvement of the BDNF/ERK signal pathway. Pharmacol Biochem Behav 2015; 136: 39-46.
[http://dx.doi.org/10.1016/j.pbb.2015.07.005] [PMID: 26176197]
[23]
Kano T, Inaba Y, D’Antuono M, Biagini G, Levésque M, Avoli M. Blockade of in vitro ictogenesis by low-frequency stimulation coincides with increased epileptiform response latency. J Neurophysiol 2015; 114(1): 21-8.
[http://dx.doi.org/10.1152/jn.00248.2015] [PMID: 25925325]
[24]
Hellmann J, Jüttner R, Roth C, et al. Repetitive magnetic stimulation of human-derived neuron-like cells activates cAMP-CREB pathway. Eur Arch Psychiatry Clin Neurosci 2012; 262(1): 87-91.
[http://dx.doi.org/10.1007/s00406-011-0217-3] [PMID: 21562895]
[25]
Tokay T, Holl N, Kirschstein T, Zschorlich V, Köhling R. High frequency magnetic stimulation induces long-term potentiation in rat hippocampal slices. Neurosci Lett 2009; 461(2): 150-4.
[http://dx.doi.org/10.1016/j.neulet.2009.06.032] [PMID: 19539714]
[26]
Roman A, Vetulani J, Nalepa I. Effect of combined treatment with paroxetine and transcranial magnetic stimulation (TMS) on the mitogen-induced proliferative response of rat lymphocytes. Pol J Pharmacol 2002; 54(6): 633-9.
[PMID: 12866718]
[27]
Hausmann A, Marksteiner J, Hinterhuber H, Humpel C. Magnetic stimulation induces neuronal c-fos via tetrodotoxin-sensitive sodium channels in organotypic cortex brain slices of the rat. Neurosci Lett 2001; 310(2-3): 105-8.
[http://dx.doi.org/10.1016/S0304-3940(01)02073-0] [PMID: 11585578]
[28]
Wang Y, Fang K, He S, Fan Y, Yu J, Zhang X. Effects of repetitive magnetic stimulation on the growth of primarily cultured hippocampus neurons in vitro and their expression of iron-containing enzymes. Neuropsychiatr Dis Treat 2019; 15: 927-34.
[http://dx.doi.org/10.2147/NDT.S199328] [PMID: 31114204]
[29]
Negahbani E, Schmidt SL, Mishal N, Fröhlich F. Neuromodulation-dependent effect of gated high-frequency, LFMS-like electric field stimulation in mouse cortical slices. Eur J Neurosci 2019; 49(10): 1288-97.
[PMID: 30450622]
[30]
Hong I, Garrett A, Maker G, Mullaney I, Rodger J, Etherington SJ. Repetitive low intensity magnetic field stimulation in a neuronal cell line: a metabolomics study. PeerJ 2018; 6: e4501.
[http://dx.doi.org/10.7717/peerj.4501] [PMID: 29576970]
[31]
Clarke D, Penrose MA, Penstone T, et al. Frequency-specific effects of repetitive magnetic stimulation on primary astrocyte cultures. Restor Neurol Neurosci 2017; 35(6): 557-69.
[http://dx.doi.org/10.3233/RNN-160708] [PMID: 29172007]
[32]
Liu T, Fu M, Arias-Carrion O, Yuan TF. Commentary: recalling memory by brain stimulation. CNS Neurol Disord Drug Targets 2017; 116(10): 1047-8.
[33]
Xu J, Cheng S, Jiao Z, et al. Fire needle acupuncture regulates Wnt/ERK multiple pathways to promote neural stem cells to differentiate into neurons in rats with spinal cord injury. CNS Neurol Disord Drug Targets 2019; 118(3): 245-55.
[34]
Wu X, Chen Z, Sun W, et al. Activation of Kir2. 3 channels by Tenidap suppresses epileptiform burst discharges in cultured hippocampal neuron. CNS Neurol Disord Drug Targets 2019; 18(8): 621-30.
[http://dx.doi.org/10.2174/1871527318666190807122623] [PMID: 31389319]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2020
Published on: 17 May, 2020
Page: [220 - 226]
Pages: 7
DOI: 10.2174/1871527319666200518100716
Price: $65

Article Metrics

PDF: 33
HTML: 2